Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8962237 | 0.82 | POLB (0.38) | SMN1; SMN2HSD17B10POLB | |
| Ammonia Solution, Strong SCHEMBL27973098 | 0.80 | POLB (0.37) | SMN1; SMN2HSD17B10POLB | |
| SCHEMBL24574899 | 0.77 | SMN1; SMN2 (0.45) | SMN1; SMN2HSD17B10POLB | |
| SCHEMBL20204605 | 0.76 | CNR1 (0.31) | — | |
| SCHEMBL25584731 | 0.76 | — | — | |
| SCHEMBL21936665 | 0.75 | SMN1; SMN2 (0.37) | SMN1; SMN2HSD17B10POLB | |
| SCHEMBL23613177 | 0.73 | ACLY (0.37) | — | |
| SCHEMBL14472418 | 0.71 | SMN1; SMN2 (0.36) | SMN1; SMN2HSD17B10POLB | |
| SCHEMBL20218595 | 0.71 | SMN1; SMN2 (0.36) | SMN1; SMN2HSD17B10POLB | |
| SCHEMBL17929908 | 0.71 | RIPK1 (0.48) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084800-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200071301-A1 | Aryi, Heteroaryl, and Heterocyclic Pharmaceutical Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071301-A1 | Aryi, Heteroaryl, and Heterocyclic Pharmaceutical Compounds for Treatment of Medical Disorders | CFD, TFPI, CFH | SMN1; SMN2 4127/4885HSD17B10 1266/4885POLB 4302/4885 |
| US-11084800-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | SMN1; SMN2 3485/4885HSD17B10 1063/4885POLB 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.